次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

女性ヘルスケア(Women's Healthcare)の世界市場:2024年に至る治療薬別、用途別予測

Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024

出版元:MarketsandMarketsLinkIcon出版元について
発行年:2020年1月
定価 Single User License(1名様ライセンス)US$4,950(米国ドル)/Multi User License(5名様)$6,650 /Corporate User License $8,150
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email
当調査レポートは英文147ページになります。
商品コード:MAM1848

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
女性ヘルスケア市場は今後成長が見込まれ、その世界市場規模は2019年で96億ドル、2024年には178億ドルに達するとレポートでは予測しています。当レポートでは、2024年に至る女性ヘルスケアの世界市場予測(市場規模US$)、治療薬別市場(PROLIA、XGEVA、FORTEO、MIRENA、NUVARING、PREMARIN、ORTHO TRI-CY LO (28)、EVISTA、RECLAST/ACLASTA、ZOMETA、MINASTRIN 24 FE、ACTONEL)、用途別市場(閉経後骨粗鬆症、避妊薬、メノポーズ、ホルモン不妊症、多発性卵巣症候群、子宮内膜症、その他)、主要国地域別市場など、詳細な市場予測データと分析を掲載しています。また市場分析、競合状況、主要メーカー企業14社プロフィール動向などの情報も交えて、女性ヘルスケア市場の現在と今後展開を予測分析していきます。

【レポート構成概要】
◆女性ヘルスケアの世界市場予測2017-2024年
・市場規模(US$)

◆治療薬別、市場-2024年
・PROLIA
・XGEVA
・FORTEO
・MIRENA
・NUVARING
・PREMARIN
・ORTHO TRI-CY LO (28)
・EVISTA
・RECLAST/ACLASTA
・ZOMETA
・MINASTRIN 24 FE
・ACTONEL
※(市場規模US$) 

◆用途別、市場-2024年
・閉経後骨粗鬆症
・避妊薬
・メノポーズ
・ホルモン不妊症
・多発性卵巣症候群
・子宮内膜症
・その他
※(市場規模US$)

◆主要国地域別市場-2024年
北米
・米国、カナダ
欧州
・ドイツ、フランス、英国
・イタリア、スペイン
・その他欧州
アジア太平洋
・日本、中国、インド
・その他アジア太平洋
中南米
中東アフリカ
※国地域別に全セグメントの細分化データ掲載、詳細は目次参照

◆市場分析
・市場ダイナミクス分析(ドライバー、機会、課題)
・市場シェア分析
・研究開発パイプライン
・競合状況

◆女性ヘルスケアの主要企業プロフィール動向
・AMGEN         
・BAYER AG     
・ELI LILLY AND COMPANY     
・MERCK & CO.
・PFIZER          
・ALLERGAN   
・JOHNSON & JOHNSON SERVICES INC.
・NOVARTIS AG            
・MYLAN NV    
・LUPIN LIMITED         
・AGILE THERAPEUTICS           
・FERRING PHARMACEUTICALS           
・BLAIREX LABORATORIES, INC.           
・APOTHECUS PHARMACEUTICAL CORPORATION
(全147頁)



【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Women's Health Care Market by Drugs (Prolia, Xgeva, Evista, Mirena, Zometa, Reclast, Nuvaring, Primarin, Actonel), Application (Female Infertility, Postmenopausal Osteoporosis, Endometriosis, Contraception, PCOS, Menopause) - Global forecast to 2024

Table of Contents

1.... INTRODUCTION

1.1             OBJECTIVES OF THE STUDY
1.2             MARKET DEFINITION
1.3             MARKET SCOPE
1.3.1              MARKETS COVERED
1.3.2              YEARS CONSIDERED FOR THE STUDY
1.4             CURRENCY
1.5             LIMITATIONS
1.6             STAKEHOLDERS

2.... RESEARCH METHODOLOGY

2.1             RESEARCH DATA
2.1.1              SECONDARY SOURCES.. 21
2.1.1.1            KEY DATA FROM SECONDARY SOURCES
2.1.2              PRIMARY SOURCES.. 22
2.1.2.1            KEY DATA FROM PRIMARY SOURCES
2.1.2.2            KEY INDUSTRY INSIGHTS
2.2             MARKET SIZE ESTIMATIONS
2.3             MARKET BREAKDOWN AND DATA TRIANGULATION
2.4             ASSUMPTIONS FOR THE STUDY

3.... EXECUTIVE SUMMARY

4.... PREMIUM INSIGHTS

4.1             WOMEN’S HEALTHCARE MARKET OVERVIEW
4.2             WOMEN’S HEALTHCARE MARKET, BY DRUG (2019–2024)
4.3             WOMEN’S HEALTHCARE MARKET, BY APPLICATION (2019 VS. 2024)
4.4             WOMEN’S HEALTHCARE MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5.... MARKET OVERVIEW

5.1             INTRODUCTION
5.2             MARKET DYNAMICS
5.2.1              MARKET DRIVERS
5.2.1.1            GROWING INCIDENCE OF CHRONIC HEALTH CONDITIONS AMONG WOMEN
5.2.1.2            DEMAND FOR CONTRACEPTIVES TO PREVENT UNINTENDED PREGNANCIES
5.2.1.3            GOVERNMENT INITIATIVES TO CURB POPULATION GROWTH
5.2.1.4            GROWING FOCUS ON PRODUCT R&D

5.2.2              MARKET OPPORTUNITIES
5.2.2.1            EMERGING MARKETS
5.2.3              MARKET CHALLENGES.. 38
5.2.3.1            RELUCTANCE TO USE CONTRACEPTIVES

6.... WOMEN’S HEALTHCARE MARKET, BY DRUG

6.1             INTRODUCTION
6.2             PROLIA
6.2.1              PROLIA ACCOUNTS FOR THE LARGEST SHARE OF THE WOMEN’S HEALTHCARE MARKET
6.3             XGEVA
6.3.1              XGEVA IS PRIMARILY MARKETED IN THE US AND EUROPEAN COUNTRIES
6.4             FORTEO
6.4.1              ELI LILLY IS EXPECTED TO EXPERIENCE A REVENUE DECLINE IN THE COMING YEARS DUE TO THE PATENT EXPIRY OF FORTEO
6.5             MIRENA
6.5.1              MIRENA IS WIDELY ACCEPTED AMONGST END USERS OWING TO THE MINIMAL SIDE-EFFECTS ASSOCIATED WITH IT
6.6             NUVARING
6.6.1              NUVARING IS ONE OF THE TOP-SELLING DRUGS FROM MERCK IN THE WOMEN’S HEALTH CATEGORY
6.7             PREMARIN
6.7.1              PREMARIN IS USED FOR THE TREATMENT OF OSTEOPOROSIS IN WOMEN
6.8             ORTHO TRI-CY LO (28)
6.8.1              GROWING NUMBER OF ANDA TO MARKET GENERIC VERSIONS OF ORTHO TRI-CY LO (28) TO HAMPER ITS SALES IN THE COMING YEARS
6.9             EVISTA
6.9.1              INTENSE GENERIC COMPETITION HAS LED TO A YEAR-ON-YEAR DECLINE IN EVISTA’S SALES
6.10          RECLAST/ACLASTA
6.10.1            ACLASTA HAS MORE BENEFITS AS COMPARED TO OTHER DRUGS
6.11          ZOMETA
6.11.1            EARLY PATENT EXPIRY OF ZOMETA IN THE US AND EUROPE HAS AFFECTED ITS SALES
6.12          MINASTRIN 24 FE
6.12.1            AVAILABILITY OF LOW-PRICED GENERIC VERSIONS OF MINASTRIN 24 FE IS ONE OF THE MAIN REASONS FOR THE LOWER SALES OF THIS DRUG
6.13          ACTONEL
6.13.1            INTENSE COMPETITION IN THE OSTEOPOROSIS MARKET HAS LED TO A SALES DECLINE IN ACTONEL IN THE LAST FEW YEARS
6.14          PIPELINE DRUGS

7.... WOMEN’S HEALTHCARE MARKET, BY APPLICATION

7.1             INTRODUCTION
7.2             POSTMENOPAUSAL OSTEOPOROSIS
7.2.1              HIGH PREVALENCE OF OSTEOPOROSIS IN WOMEN HAS PROMPTED COMPANIES TO FOCUS ON THIS THERAPEUTIC AREA.. 66
7.3             CONTRACEPTIVES
7.3.1              BENEFITS OFFERED BY CONTRACEPTIVES DRIVING THEIR DEMAND AMONG END USERS
7.4             MENOPAUSE
7.4.1              DEMAND FOR NON-HORMONAL THERAPIES HAS INCREASED OVER THE LAST FEW YEARS
7.5             HORMONAL INFERTILITY
7.5.1              INCREASING AWARENESS ABOUT OVULATION HEALTH TO SUPPORT MARKET GROWTH
7.6             POLYCYSTIC OVARY SYNDROME
7.6.1              GROWING PREVALENCE OF PCOS IS RESPONSIBLE FOR MARKET GROWTH
7.7             ENDOMETRIOSIS
7.7.1              ORILISSA IS THE FIRST AND ONLY ORAL TREATMENT SPECIFICALLY AVAILABLE FOR WOMEN WITH ENDOMETRIOSIS PAIN
7.8             OTHER APPLICATIONS

8.... WOMEN’S HEALTHCARE MARKET, BY REGION

8.1             INTRODUCTION
8.2             NORTH AMERICA
8.2.1              US
8.2.1.1            STRONG ECONOMY AND HIGH CONTRACEPTION AWARENESS ARE KEY FACTORS DRIVING MARKET GROWTH IN THE US
8.2.2              CANADA
8.2.2.1            GROWING PREVALENCE OF PCOS AND OBESITY TO SUPPORT MARKET GROWTH IN CANADA
8.3             EUROPE
8.3.1              GERMANY
8.3.1.1            GERMANY HOLDS THE LARGEST SHARE OF THE WOMEN’S HEALTHCARE MARKET IN EUROPE
8.3.2              UK
8.3.2.1            GOVERNMENT SUPPORT AND FAVORABLE TRAINING PROGRAMS ARE MAJOR MARKET DRIVERS IN THE UK
8.3.3              FRANCE
8.3.3.1            HIGH PREVALENCE OF LIFESTYLE DISORDERS AMONG WOMEN IN FRANCE TO SUPPORT MARKET GROWTH
8.3.4              ITALY
8.3.4.1            RELATIVELY HIGH AWARENESS OF CONTRACEPTIVES TO DRIVE MARKET GROWTH IN ITALY
8.3.5              SPAIN
8.3.5.1            IMPROVED HEALTHCARE EXPENDITURE TO SUPPORT THE MARKET IN SPAIN
8.3.6              REST OF EUROPE
8.4             ASIA PACIFIC
8.4.1              JAPAN
8.4.1.1            JAPAN DOMINATES THE APAC MARKET FOR WOMEN’S HEALTHCARE
8.4.2              CHINA
8.4.2.1            GROWING POPULATION AND URBANIZATION ARE FACTORS RESPONSIBLE FOR THE GROWTH OF THE MARKET IN CHINA
8.4.3              INDIA
8.4.3.1            INCREASING GOVERNMENT INITIATIVES TO CURB POPULATION GROWTH WILL DRIVE MARKET GROWTH IN INDIA
8.4.4              REST OF APAC
8.5             LATIN AMERICA
8.5.1              INCREASING LIFESTYLE DISEASES AND AWARENESS AMONG WOMEN TO DRIVE MARKET GROWTH IN LATIN AMERICA
8.6             MIDDLE EAST & AFRICA
8.6.1              INCREASING GOVERNMENT INITIATIVES TO CURB POPULATION GROWTH WILL DRIVE MARKET GROWTH IN INDIA.. 108

9.... COMPETITIVE LANDSCAPE

9.1             OVERVIEW
9.2             MARKET SHARE ANALYSIS
9.3             COMPETITIVE LEADERSHIP MAPPING
9.3.1              VISIONARY LEADERS.. 112
9.3.2              DYNAMIC DIFFERENTIATORS
9.3.3              INNOVATORS
9.3.4              EMERGING COMPANIES

10.. COMPANY PROFILES

(BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW)*
10.1          AMGEN
10.2          BAYER AG
10.3          ELI LILLY AND COMPANY
10.4          MERCK & CO.
10.5          PFIZER
10.6          ALLERGAN
10.7          JOHNSON & JOHNSON SERVICES INC.
10.8          NOVARTIS AG
10.9          MYLAN NV
10.10        LUPIN LIMITED
10.11        AGILE THERAPEUTICS
10.12        FERRING PHARMACEUTICALS
10.13        BLAIREX LABORATORIES, INC.
10.14        APOTHECUS PHARMACEUTICAL CORPORATION
*BUSINESS OVERVIEW, PRODUCTS OFFERED, RECENT DEVELOPMENTS, SWOT ANALYSIS, MNM VIEW MIGHT NOT BE CAPTURED IN CASE OF UNLISTED COMPANIES.
11.. APPENDIX

LIST OF TABLES

TABLE 1              WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 2              PROLIA: PRODUCT HIGHLIGHTS
TABLE 3              WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY REGION,
2017–2024 (USD MILLION)
TABLE 4              NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PROLIA,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 5              EUROPE: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 6              APAC: WOMEN’S HEALTHCARE MARKET FOR PROLIA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 7              XGEVA: PRODUCT HIGHLIGHTS
TABLE 8              WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY REGION,
2017–2024 (USD MILLION)
TABLE 9              NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR XGEVA,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 10            EUROPE: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 11            APAC: WOMEN’S HEALTHCARE MARKET FOR XGEVA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 12            FORTEO: PRODUCT HIGHLIGHTS
TABLE 13            WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY REGION,
2017–2024 (USD MILLION)
TABLE 14            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 15            EUROPE: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 16            APAC: WOMEN’S HEALTHCARE MARKET FOR FORTEO, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 17            MIRENA: PRODUCT HIGHLIGHTS
TABLE 18            WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY REGION,
2017–2024 (USD MILLION)
TABLE 19            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MIRENA,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 20            EUROPE: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 21            APAC: WOMEN’S HEALTHCARE MARKET FOR MIRENA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 22            NUVARING: PRODUCT HIGHLIGHTS
TABLE 23            WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY REGION,
2017–2024 (USD MILLION)
TABLE 24            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 25            EUROPE: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 26            APAC: WOMEN’S HEALTHCARE MARKET FOR NUVARING, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 27            PREMARIN: PRODUCT HIGHLIGHTS
TABLE 28            WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY REGION,
2017–2024 (USD MILLION)
TABLE 29            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR PREMARIN,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 30            EUROPE: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 31            APAC: WOMEN’S HEALTHCARE MARKET FOR PREMARIN, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 32            ORTHO TRI-CY LO (28): PRODUCT HIGHLIGHTS
TABLE 33            WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28), BY REGION,
2017–2024 (USD MILLION)
TABLE 34            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28),
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 35            EUROPE: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28),
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 36            APAC: WOMEN’S HEALTHCARE MARKET FOR ORTHO TRI-CY LO (28),
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 37            EVISTA: PRODUCT HIGHLIGHTS
TABLE 38            WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY REGION,
2017–2024 (USD MILLION)
TABLE 39            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 40            EUROPE: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 41            APAC: WOMEN’S HEALTHCARE MARKET FOR EVISTA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 42            RECLAST/ACLASTA: PRODUCT HIGHLIGHTS
TABLE 43            WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA, BY REGION,
2017–2024 (USD MILLION)
TABLE 44            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 45            EUROPE: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 46            APAC: WOMEN’S HEALTHCARE MARKET FOR RECLAST/ACLASTA,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 47            ZOMETA: PRODUCT HIGHLIGHTS
TABLE 48            WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY REGION,
2017–2024 (USD MILLION)
TABLE 49            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 50            EUROPE: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 51            APAC: WOMEN’S HEALTHCARE MARKET FOR ZOMETA, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 52            MINASTRIN 24 FE: PRODUCT HIGHLIGHTS
TABLE 53            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MINASTRIN 24 FE,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 54            ACTONEL: PRODUCT HIGHLIGHTS
TABLE 55            WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY REGION,
2017–2024 (USD MILLION)
TABLE 56            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 57            EUROPE: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 58            APAC: WOMEN’S HEALTHCARE MARKET FOR ACTONEL, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 59            INDICATIVE LIST OF DRUGS IN PHASE III
TABLE 60            WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)
TABLE 61            WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS,
BY REGION, 2017–2024 (USD MILLION)
TABLE 62            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 63            EUROPE: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 64            APAC: WOMEN’S HEALTHCARE MARKET FOR POSTMENOPAUSAL OSTEOPOROSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 65            WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY REGION,
2017–2024 (USD MILLION)
TABLE 66            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 67            EUROPE: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 68            APAC: WOMEN’S HEALTHCARE MARKET FOR CONTRACEPTIVES, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 69            WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY REGION,
2017–2024 (USD MILLION)
TABLE 70            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 71            EUROPE: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 72            APAC: WOMEN’S HEALTHCARE MARKET FOR MENOPAUSE, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 73            WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY REGION, 2017–2024 (USD MILLION)
TABLE 74            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 75            EUROPE: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 76            APAC: WOMEN’S HEALTHCARE MARKET FOR HORMONAL INFERTILITY,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 77            WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME,
BY REGION, 2017–2024 (USD MILLION)
TABLE 78            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 79            EUROPE: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 80            APAC: WOMEN’S HEALTHCARE MARKET FOR POLYCYSTIC OVARY SYNDROME,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 81            WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY REGION,
2017–2024 (USD MILLION)
TABLE 82            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 83            EUROPE: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD THOUSAND)
TABLE 84            APAC: WOMEN’S HEALTHCARE MARKET FOR ENDOMETRIOSIS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 85            WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY REGION,
2017–2024 (USD MILLION)
TABLE 86            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 87            EUROPE: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS,
BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 88            APAC: WOMEN’S HEALTHCARE MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2017–2024 (USD MILLION)
TABLE 89            WOMEN’S HEALTHCARE MARKET, BY REGION, 2017–2024 (USD MILLION)
TABLE 90            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 91            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG,
2017–2024 (USD MILLION)
TABLE 92            NORTH AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 93            US: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 94            US: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 95            CANADA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 96            CANADA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 97            EUROPE: WOMEN’S HEALTHCARE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 98            EUROPE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 99            EUROPE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 100          GERMANY: WOMEN’S HEALTHCARE MARKET, BY DRUG,
2017–2024 (USD MILLION)
TABLE 101          GERMANY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 102          UK: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 103          UK: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 104          FRANCE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 105          FRANCE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 106          ITALY: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 107          ITALY: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 108          SPAIN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 109          SPAIN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD THOUSAND)
TABLE 110          ROE: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 111          ROE: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 112          ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY COUNTRY,
2017–2024 (USD MILLION)
TABLE 113          ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY DRUG,
2017–2024 (USD MILLION)
TABLE 114          ASIA PACIFIC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 115          JAPAN: INDICATIVE LIST OF CONFERENCES
TABLE 116          JAPAN: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 117          JAPAN: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 118          CHINA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 119          CHINA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 120          INDIA: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 121          INDIA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 122          ROAPAC: WOMEN’S HEALTHCARE MARKET, BY DRUG, 2017–2024 (USD MILLION)
TABLE 123          ROAPAC: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 124          LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY DRUG,
2017–2024 (USD MILLION)
TABLE 125          LATIN AMERICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION,
2017–2024 (USD MILLION)
TABLE 126          MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY DRUG,
2017–2024 (USD MILLION)
TABLE 127          MIDDLE EAST & AFRICA: WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2017–2024 (USD MILLION)

LIST OF FIGURES

FIGURE 1            RESEARCH DESIGN
FIGURE 2            BREAKDOWN OF PRIMARY INTERVIEWS
FIGURE 3            BOTTOM-UP APPROACH
FIGURE 4            TOP-DOWN APPROACH
FIGURE 5            DATA TRIANGULATION METHODOLOGY
FIGURE 6            WOMEN’S HEALTHCARE MARKET, BY DRUG, 2019 VS. 2024 (USD MILLION)
FIGURE 7            WOMEN’S HEALTHCARE MARKET, BY APPLICATION, 2019 VS. 2024 (USD MILLION)
FIGURE 8            GEOGRAPHICAL SNAPSHOT OF THE WOMEN’S HEALTHCARE MARKET
FIGURE 9            GROWING INCIDENCE OF CHRONIC HEALTH CONDITIONS AMONG WOMEN IS A MAJOR FACTOR DRIVING THE WOMEN’S HEALTHCARE MARKET
FIGURE 10          PROLIA TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
FIGURE 11          POSTMENOPAUSAL OSTEOPOROSIS TO DOMINATE THE WOMEN’S HEALTHCARE APPLICATIONS MARKET DURING THE FORECAST PERIOD
FIGURE 12          NORTH AMERICA IS THE FASTEST-GROWING REGIONAL MARKET FOR WOMEN’S HEALTHCARE PRODUCTS
FIGURE 13          WOMEN’S HEALTHCARE MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES
FIGURE 14          NORTH AMERICA: WOMEN’S HEALTHCARE MARKET SNAPSHOT
FIGURE 15          EUROPE: WOMEN’S HEALTHCARE MARKET SNAPSHOT
FIGURE 16          WOMEN’S HEALTHCARE MARKET SHARE ANALYSIS, BY KEY PLAYER, 2018
FIGURE 17          COMPETITIVE LEADERSHIP MAPPING OF THE WOMEN’S HEALTHCARE
MARKET, 2018
FIGURE 18          AMGEN: COMPANY SNAPSHOT
FIGURE 19          BAYER AG: COMPANY SNAPSHOT
FIGURE 20          ELI LILLY AND COMPANY: COMPANY SNAPSHOT
FIGURE 21          MERCK & CO.: COMPANY SNAPSHOT
FIGURE 22          PFIZER: COMPANY SNAPSHOT
FIGURE 23          ALLERGAN: COMPANY SNAPSHOT
FIGURE 24          JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT
FIGURE 25          NOVARTIS AG: COMPANY SNAPSHOT
FIGURE 26          MYLAN NV: COMPANY SNAPSHOT
FIGURE 27          LUPIN LIMITED: COMPANY SNAPSHOT



掲載企業リスト

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。